Overview

An Evaluation of the Biodistribution and Imaging Characteristics of ABT-806i (111In-ABT-806) in Subjects With Advanced Solid Tumor Types

Status:
Completed
Trial end date:
2012-12-01
Target enrollment:
Participant gender:
Summary
This is an open label study designed to evaluate the biodistribution and imaging characteristics of ABT-806i (111In-ABT-806) in subjects with advanced solid tumor types.
Phase:
Phase 1
Details
Lead Sponsor:
AbbVie (prior sponsor, Abbott)